Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-643-7 | CAS number: 109-06-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics
- Type of information:
- migrated information: read-across based on grouping of substances (category approach)
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: compliant with guidelines from the European Chemical Agency for assessment of toxicokinetic behaviour of the substance to the extent that can be derived from the relevant available information.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 010
- Report date:
- 2010
Materials and methods
- Objective of study:
- toxicokinetics
Test guideline
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- Assessment of toxicokinetic behaviour of the substance to the extent that can be derived from the relevant available information.
- GLP compliance:
- no
Test material
- Reference substance name:
- Pyridine
- EC Number:
- 203-809-9
- EC Name:
- Pyridine
- Cas Number:
- 110-86-1
- Molecular formula:
- C5H5N
- IUPAC Name:
- pyridine
Constituent 1
- Radiolabelling:
- no
Results and discussion
Main ADME resultsopen allclose all
- Type:
- absorption
- Results:
- Pyridine and methyl derivatives are all readily absorbed in the respiratory tract, by dermal absorption and through the gastrointestinal tract.
- Type:
- distribution
- Results:
- Pyridine and methyl derivatives are widely distributed to tissues with the primary tissues being kidney > liver > plasma > lung. They are not likely distributed to fat or breast milk.
- Type:
- metabolism
- Results:
- Pyridine and methyl derivatives all appear to undergo metabolism by cytochrome P450 enzymes. Pyridine-N-oxide and N-methylpyridinium appear to be the primary metabolites in both animal and human studies.
- Type:
- excretion
- Results:
- Pyridine, its metabolites and derivatives are excreted primarily in the urine, but also in exhaled air and feces.
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- Pyridine and its derivatives are all colorless liquids at room temperature with disagreeable odors. Each of the substances exerts a relatively high vapor pressure suggesting that the substance may volatilize and thus be potentially inhaled as a vapor. Pyridine and the picoline derivatives all have very high water solubility, relatively low log octanol water partition coefficients and low molecular weights which suggest greater potential for absorption across the skin and gastrointestinal tract. Acute dermal toxicity studies of 3-picoline confirm that it is absorbed across the skin (Tice and Brevard, 1999) and in animal studies pyridine is reported to be well absorbed across the gastrointestinal tract (IARC, 2000). Pyridine has been demonstrated to be readily absorbed through inhalation ingestion and dermal exposure (Reinhardt and Britell, 1981).
- Details on distribution in tissues:
- Inhalation of pyridine results in olfactory mucosal lesions in rats. Oral administration to mice in chronic studies results in an increase in hepatic tumors while oral administration to rats results in an increase in renal tumors. Acute and sub-acute oral toxicity studies if 2-picoline do not indicate that the kidney and liver are target organs of toxicity (Til et al., (1975). Subchronic inhalation studies of 3-picoline revealed increased liver weights in exposed rats (Tice and Brevard, 1999). Subchronic studies conducted with pyridine (NTP, 2000) and the three picoline derivatives indicate that the liver and kidney are target organs of toxicity. The primary organs of distribution of pyridine and the picoline derivatives are the olefactory epithelium and the upper respiratory tract, the liver and the kidney. For pyridine following intraperitoneal injection orf inhalation the concentrations distributed to tissues were in the order kidney > liver > plasma > lung (Scholl and Iba, 1997). The high water solubility and low partitioning into octanol of pyridine and the picoline derivatives indicates that each of the substances is unlikely to accumulate in body fats or breast milk.
- Details on excretion:
- Pyridine and its metabolites are eliminated primarily in the urine. Pyridine is also excreted in exhaled air and in feces to a lesser extent (SCOEL, 2004). The elimination half life of pyridine was 17 hours following a single 100 mg/kg intraperitoneal injection and was 8 hours following the last exposure of a 3-day, 8 hour/day exposure to 200 ppm by inhalation (Scholl and Iba, 1997). The shorter elimination half life is possibly due to induction of metabolic enzymes. Pyridine induces CYP2E1 and CYP1A1 metabolism (Scholl and Iba, 1997). The latter induction has been shown to be sexually dimorphic. There is no gender difference in the plasma elimination rate of pyridine after intraperitoneal administration however (Iba et al., 1999). 3-Picoline administered intraperitoneally to guinea pigs, rabbits, mice and ferrets resulted in urinary excretion of the N-oxide compound (approximately 10% in rats, 40% in mice and in guinea pigs) (Gorrod et al., 1980; AIHA, 1988).
Metabolite characterisation studies
- Metabolites identified:
- yes
- Details on metabolites:
- Pyridine was shown to induce lesions in the olefactory epithelium but not the nasal, respiratory or transitional epithelium, which is explained by a higher rate of metabolism in the olefactory epithelium to N-oxide metabolites (Nikula and Lewis, 1994). Pyridine is metabolized by cytochrome P450 2E1 and 4B (Kim et al., 1990) and has been shown to enhance the expression of several isozymes of cytochrome P450 including 2E1, 1A1, 1A2, 2B1 and 2B2 (Kim and Novak, 1990). Pyridine has been shown to induce CYP1A1 in multiple organs in rats, mice and cultured human lung explants (Iba et al, 2000). N-methyl and N-oxide metabolites of pyridine are also able to induce CYP1A1 metabolism to a similar extent as parent compound (Iba et al., 2000). The primary metabolites of pyridine are pyridine-N-oxide, 2-pyridone, 4-pyridone, 3-hydroxypyridine, and N-methyl pyridinium ion (SCOEL, 2004). While the primary source of metabolism data on pyridine is from animal studies, two healthy human volunteers were given 3.4 mg pyridine in orange juice and the excretion of metabolites was determined. The primary metabolite excreted was pyridine-N-oxide (32% of administered dose) and N-methylpyridinium (12% of the dose) collected in a 24 hour urine sample (D’Souza et al., 1980; SCOEL, 2004).
Pyridine and its metabolites are eliminated primarily in the urine. Pyridine is also excreted in exhaled air and in feces to a lesser extent (SCOEL, 2004). The elimination half life of pyridine was 17 hours following a single 100 mg/kg intraperitoneal injection and was 8 hours following the last exposure of a 3-day, 8 hour/day exposure to 200 ppm by inhalation (Scholl and Iba, 1997). The shorter elimination half life is possibly due to induction of metabolic enzymes. Pyridine induces CYP2E1 and CYP1A1 metabolism (Scholl and Iba, 1997). The latter induction has been shown to be sexually dimorphic. There is no gender difference in the plasma elimination rate of pyridine after intraperitoneal administration however (Iba et al., 1999).
3-Picoline administered intraperitoneally to guinea pigs, rabbits, mice and ferrets resulted in urinary excretion of the N-oxide compound (approximately 10% in rats, 40% in mice and in guinea pigs) (Gorrod et al., 1980; AIHA, 1988).
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): low bioaccumulation potential based on study results
Pyridine and its methyl derivatives are absorbed via inhalation, oral and dermal exposures. They are distributed into the water compartment as evidenced by highest levels in the kidney and eliminated primarily in the urine. Pyridine and its derivatives are metabolised by CYP enzymes in the liver, with primary metabolites being pyridine-N-oxide, 2-pyridone, 4-pyridone, 3-hydroxypyridine, and N-methyl pyridinium ion. These substances have a low risk of bioaccumulating in body fat or milk.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.